Does the justice system oversee big pharma and its drug patent culture? Who does this culture benefit the most- pharma or the patients? Here is a case study in India where the generic drug manufacturers won against a major pharma company, with many seeing this as a victory for patients in terms of drug afforadability. Read on this opinion piece here…
Missed the SIULondon event on March 20th? Here's the event summary covering the advice from both innovators and investors to aspiring entrepreneurs.
Timing and the right people are everything when it comes to translating your science into a business. Brian Graves from Imperial Innovations joined us for the 4th session of the SIU360-Oxford and told us about the strategies for selecting the right customer, the right partners and the right avenues to be successful in translation of science into business.
'Open Innovation' is one of those terms that appear often in business-related news and discussions but don't reveal their definition in the first instance. In this article, we discuss what it is and what it's not, the risks and advantages associated with it while highlighting examples where it is used by companies.
What does Point-of-care-testing (POCT) mean for the average patient?